Leuprolide

Leuprolide Acetate (Lupron) — GnRH Agonist

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Established

At a Glance

A GnRH agonist represented through the current Lupron Depot product label; formulations and labeled uses are not interchangeable.

Plain English

Leuprolide is used in tightly defined prescription settings. The product matters: the route, schedule, indication, and risks must come from the current label for that exact product.

Overview

Leuprolide acetate is a synthetic GnRH agonist. This record is limited to the current Lupron Depot product anchor and its labeled indications; it does not treat depot products, short-acting injections, implants, or international brands as interchangeable. Continuous agonist exposure can initially increase gonadal hormone concentrations before later suppression, a product-label warning relevant to some patients.

Research Summary

Current Lupron Depot labeling establishes the represented product's authorized indications and risk information. This record does not make a comparative efficacy claim across all leuprolide products, GnRH agonists, antagonists, or clinical contexts.

Research Areas

  • GnRH agonist pharmacology
  • Labeled Lupron Depot uses

Safety & Risks

Serious Risks

  • An initial rise in testosterone can occur during early treatment and may worsen symptoms in susceptible patients with advanced prostate cancer.
  • Longer-term sex-hormone suppression can affect bone density; label-directed monitoring and indication-specific management are required.
  • Hypersensitivity reactions, including anaphylactic or anaphylactoid reactions, are reported in product labeling.
United States
Leuprolide is represented here through current Lupron Depot labeling; FDA-approved indications, formulations, routes, and schedules are product-specific.
United Kingdom
Not assessed in this record.
Australia
Not assessed in this record.
Canada
Not assessed in this record.